Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frej Fyhrquist

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Experimental Gerontology|March 6, 2012
Physical activity in midlife and telomere length measured in old ageSalla Savela, Outi Saijonmaa, Timo E Strandberg, et al.
Hypertension (Dallas, Tex. : 1979)|March 29, 2006
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension StudyPuneet Narayan, Vasilios Papademetriou, Kristian Wachtell, et al.
Pharmacogenomics|March 30, 2017
Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responsesJenni M Rimpelä, Kimmo K Kontula, Frej Fyhrquist, et al.
Nutrients|January 27, 2021
Effects of Randomized Controlled Infancy-Onset Dietary Intervention on Leukocyte Telomere Length-The Special Turku Coronary Risk Factor Intervention Project (STRIP)Niina Pitkänen, Katja Pahkala, Suvi P Rovio, et al.
BMC Medical Genetics|January 22, 2005
Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertensionTuula Hannila-Handelberg, Kimmo Kontula, Ilkka Tikkanen, et al.
Human Molecular Genetics|August 13, 2003
A genome wide scan for early onset primary hypertension in ScandinaviansFredrik von Wowern, Kristina Bengtsson, Cecilia M Lindgren, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Pharmacogenetics and Genomics|January 13, 2010
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE studyBørge G Nordestgaard, Kimmo Kontula, Marianne Benn, et al.
American Heart Journal|December 17, 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Experimental Gerontology|March 6, 2012
Physical activity in midlife and telomere length measured in old ageSalla Savela, Outi Saijonmaa, Timo E Strandberg, et al.
Hypertension (Dallas, Tex. : 1979)|March 29, 2006
Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension StudyPuneet Narayan, Vasilios Papademetriou, Kristian Wachtell, et al.
Pharmacogenomics|March 30, 2017
Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responsesJenni M Rimpelä, Kimmo K Kontula, Frej Fyhrquist, et al.
Nutrients|January 27, 2021
Effects of Randomized Controlled Infancy-Onset Dietary Intervention on Leukocyte Telomere Length-The Special Turku Coronary Risk Factor Intervention Project (STRIP)Niina Pitkänen, Katja Pahkala, Suvi P Rovio, et al.
BMC Medical Genetics|January 22, 2005
Common variants of the beta and gamma subunits of the epithelial sodium channel and their relation to plasma renin and aldosterone levels in essential hypertensionTuula Hannila-Handelberg, Kimmo Kontula, Ilkka Tikkanen, et al.
Human Molecular Genetics|August 13, 2003
A genome wide scan for early onset primary hypertension in ScandinaviansFredrik von Wowern, Kristina Bengtsson, Cecilia M Lindgren, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Pharmacogenetics and Genomics|January 13, 2010
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE studyBørge G Nordestgaard, Kimmo Kontula, Marianne Benn, et al.
American Heart Journal|December 17, 2008
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) studyMichael Hecht Olsen, Kristian Wachtell, Gareth Beevers, et al.
Pageof 6